These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27445164)

  • 1. Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients.
    Badve SV; Pascoe EM; Burke M; Clayton PA; Campbell SB; Hawley CM; Lim WH; McDonald SP; Wong G; Johnson DW
    Clin J Am Soc Nephrol; 2016 Oct; 11(10):1845-1855. PubMed ID: 27445164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes in kidney transplant recipients receiving long-term therapy with inhibitors of the mammalian target of rapamycin.
    Cortazar F; Molnar MZ; Isakova T; Czira ME; Kovesdy CP; Roth D; Mucsi I; Wolf M
    Am J Transplant; 2012 Feb; 12(2):379-87. PubMed ID: 22054244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mammalian Target of Rapamycin Inhibitor Monotherapy: Efficacy in Renal Transplantation.
    Franco A; Más-Serrano P; Perez Contreras J; Jiménez L; Rodriguez D; Olivares J
    Transplant Proc; 2015 Oct; 47(8):2364-7. PubMed ID: 26518928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretransplant Cancer in Kidney Recipients in Relation to Recurrent and De Novo Cancer Incidence Posttransplantation and Implications for Graft and Patient Survival.
    Unterrainer C; Opelz G; Döhler B; Süsal C;
    Transplantation; 2019 Mar; 103(3):581-587. PubMed ID: 30418430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of prevalent vascular disease with allograft failure and mortality in live-donor kidney transplant recipients - a retrospective cohort study.
    Mainra R; Wong G; Pilmore H; Lim WH
    Transpl Int; 2019 Nov; 32(11):1161-1172. PubMed ID: 31241216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-Transplant Hypophosphatemia and the Risk of Death-Censored Graft Failure and Mortality after Kidney Transplantation.
    van Londen M; Aarts BM; Deetman PE; van der Weijden J; Eisenga MF; Navis G; Bakker SJL; de Borst MH;
    Clin J Am Soc Nephrol; 2017 Aug; 12(8):1301-1310. PubMed ID: 28546442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients.
    Opelz G; Unterrainer C; Süsal C; Döhler B
    Nephrol Dial Transplant; 2016 Aug; 31(8):1360-7. PubMed ID: 27190384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Mammalian Target of Rapamycin Inhibitors for Pancreas Transplant Immunosuppression Is Associated With Improved Allograft Survival and Improved Early Patient Survival.
    Siskind EJ; Liu C; Collins DT; Emery E; Steen E; Tran E; Stodghill J; Piper J; Jonsson J; Ortiz J
    Pancreas; 2019; 48(5):644-651. PubMed ID: 31091210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus and Long-term Clinical Outcomes in Kidney Transplant Recipients: A Registry-based 10-year Follow-up of 5 Randomized Trials.
    Ying T; Wong G; Lim WH; Clayton P; Kanellis J; Pilmore H; Campbell S; O'Connell PJ; Russ G; Chadban S
    Transplantation; 2019 Aug; 103(8):1705-1713. PubMed ID: 30365464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonmelanoma Skin Cancers After Kidney Transplant: Our 15 Years of Experience With Mammalian Target of Rapamycin Inhibitors.
    Okut G; Alp A; Tatar E; Simsek C; Tugmen C; Uslu A
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):236-239. PubMed ID: 28260475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients.
    Murray SL; Daly FE; O'Kelly P; O'Leary E; Deady S; O'Neill JP; Dudley A; Rutledge NR; McCormick A; Houlihan DD; Williams Y; Morris PG; Ni Raghallaigh S; Moloney FJ; Sexton DJ; Conlon PJ
    Ren Fail; 2020 Nov; 42(1):607-612. PubMed ID: 32605413
    [No Abstract]   [Full Text] [Related]  

  • 12. Mortality and Allograft Loss Trends Among US Pediatric Kidney Transplant Recipients With and Without Focal Segmental Glomerulosclerosis.
    Wang CS; Gander J; Patzer RE; Greenbaum LA
    Am J Kidney Dis; 2018 Mar; 71(3):392-398. PubMed ID: 29277509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine.
    Lim WH; Russ GR; Wong G; Pilmore H; Kanellis J; Chadban SJ
    Kidney Int; 2017 Apr; 91(4):954-963. PubMed ID: 28109543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of Kidney Transplantation Abroad: A Single-Center Canadian Cohort Study.
    Quach K; Sultan H; Li Y; Famure O; Kim SJ
    Prog Transplant; 2016 Mar; 26(1):5-12. PubMed ID: 27136244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
    Höcker B; Tönshoff B
    Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic Review on Role of Mammalian Target of Rapamycin Inhibitors as an Alternative to Calcineurin Inhibitors in Renal Transplant: Challenges and Window to Excel.
    Kumar J; Bridson JM; Sharma A; Halawa A
    Exp Clin Transplant; 2017 Jun; 15(3):241-252. PubMed ID: 27915965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Pretransplant Cancer and Survival in Kidney Transplant Recipients.
    Dahle DO; Grotmol T; Leivestad T; Hartmann A; Midtvedt K; Reisæter AV; Mjøen G; Pihlstrøm HK; Næss H; Holdaas H
    Transplantation; 2017 Oct; 101(10):2599-2605. PubMed ID: 28207636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De novo or early conversion to everolimus and long-term cancer outcomes in kidney transplant recipients: A trial-based linkage study.
    Ying T; Wong G; Lim W; Kanellis J; Pilmore H; Campbell S; Masterson R; Walker R; O'Connell P; Russ G; Chadban S
    Am J Transplant; 2018 Dec; 18(12):2977-2986. PubMed ID: 29802791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI.
    Sánchez-Escuredo A; Diekmann F; Revuelta I; Esforzado N; Ricart MJ; Cofán F; Torregrosa JV; Peri L; Ruiz Á; Campistol JM; Oppenheimer F
    Transpl Int; 2016 Mar; 29(3):362-8. PubMed ID: 26678359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion to mammalian target of rapamycin inhibitors in kidney transplant recipients with de novo cancers.
    Cheung CY; Man Ma MK; Chak WL; Chau KF; Tang SCW
    Oncotarget; 2017 Jul; 8(27):44833-44841. PubMed ID: 28160552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.